| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Sep 30, 2026 | Almirall Advances Skin Science and Shares New Evidence Across Its Dermatology Portfolio at EADV 2026 | |
| Jul 24, 2026 | Almirall H1 2026 Results | Almirall, S.A. (ALM), a global pharmaceutical company dedicated to medical dermatology, today announced its financial results for the first half of 2026. The company delivered solid H1 2026 results, with Net Sales growing 7.5% YoY to €602.7... |
| Jul 20, 2026 | Almirall Announces EMA Acceptance for Filing of Paediatric Registration of Ebglyss (Lebrikizumab) in Atopic Dermatitis in Children 6 Months and Older | Almirall, S.A. (ALM), a global biopharmaceutical company focused on medical dermatology, today announced that the European Medicines Agency (EMA) has accepted the submission of the extension of the Marketing Authorisation Application (MAA) ... |
| Feb 23, 2026 | Almirall’s 2025 Results | Almirall, S.A. (ALM):
“2025 was another important year for Almirall as we continue to deliver against our sustained growth trajectory and further expand our leadership in medical dermatology. Another year of double-digit growth of both net ... |
| Jan 16, 2026 | Almirall Announces “LumiNE”, a Phase III Clinical Study Assessing the Efficacy of Lebrikizumab for the Treatment of Nummular Eczema | Almirall, S.A. (ALM), a global pharmaceutical company dedicated to medical dermatology, announces the planned start of a phase III study assessing the efficacy and safety of Lebrikizumab (Ebglyss®, currently approved for the treatment of mo... |
| Jan 16, 2026 | Almirall Presents R&D Pipeline Advances Supported by Sustained Growth and Leadership in Medical Dermatology at J.P. Morgan Healthcare Conference | Almirall, S.A. (ALM), a global pharmaceutical company dedicated to medical dermatology, is participating in the 44th J.P. Morgan Healthcare Conference 2026, taking place from 12th to 14th January 2026 in San Francisco, to provide an update ... |
| Nov 10, 2025 | Almirall’s 2025 9M Results | Almirall, S.A. (ALM) a global biopharmaceutical company based in Barcelona, today announced its financial results for the first nine months of 2025. Almirall continues to deliver its sustained growth trajectory based on strong sales perform... |
| Nov 10, 2025 | Simcere's IL-2 Mutant Fusion Protein SIM0278 Entered Phase II Clinical Trial Stage | NANJING, China, Nov. 10, 2025 /PRNewswire/ -- Simcere Pharmaceutical Group (2096.HK) announced that its regulatory T cells（Treg）-preferential IL-2 mutant Fc fusion protein (IL-2 mu-Fc), SIM0278, has officially entered a Phase II clinical st... |
| Nov 10, 2025 | [CIIE] Simcere to Start Producing Swiss Insomnia Drug in China, Building Manufacturing Capabilities for Global Supply | (Yicai) Nov. 10 -- Simcere Pharmaceutical Group showed its redefined cross-border collaboration model at the eighth China International Import Expo, with the Chinese company to soon start manufacturing in China an insomnia drug it licensed ... |
| May 29, 2025 | AI Meets Audit Powerhouse: Qualifyze Launches Quality Insights Platform to Help Global Pharma Manage Supplier Site Risk | FRANKFURT, Germany, May 29, 2025 /PRNewswire/ -- Qualifyze, already the global leader in third-party audit services for the pharmaceutical industry, announces the launch of Quality Insights Platform, an AI-powered platform that transforms t... |
| Aug 16, 2024 | A New Dawn in Cancer Research: AI and Funding Unite for Hope | In the battle against cancer, innovation is the sword and funding is the shield. Two recent developments highlight this truth: a groundbreaking collaboration between Absci Corporation and Memorial Sloan Kettering Cancer Center (MSK), and a ... |
| Aug 12, 2024 | Absci and MSK Collaborate on Generative AI Drug Discovery | What You Should Know:
– Absci Corporation, a leader in generative AI drug creation, today announced a strategic collaboration with Memorial Sloan Kettering Cancer Center (MSK) to develop up to six novel cancer therapeutics.
– By combining A... |
| Jul 10, 2024 | Antonin (Tony) de Fougerolles appointed as new Chair of etherna | Brings foundational experience in mRNA and LNP therapeutics given prior executive leadership roles at Moderna & Alnylam
Will take an active role in expanding partnerships with biopharma
Integrated partnership offering to customers remai... |
| May 31, 2024 | Almirall participates in Global Health Summit to raise awareness of the mental health burden of skin diseases | The mental load is a massive part of the condition, there's all of these layers, and I think it's so important we keep talking about all facets of this condition that affect people differently,”
— declared Linzi Dunlevy, IFPA amba... |
| Mar 13, 2024 | Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases | |
| Oct 6, 2022 | Simcere agree license deal of $492M USD with Almirall | Almirall Logo
Simcere Logo
Almirall granted exclusive rights to commercialise SIM0278 for all indications outside the Greater China region, (Mainland China, Hong Kong, Macau and Taiwan)
We are excited to have reached agreement with Almirall... |
| Sep 29, 2022 | Simcere and Almirall Enter into a Licensing Agreement for IL-2 mu-Fc | Simcere will receive a $15 million upfront payment, and up to $492 million in development and commercial milestone payments considering successful achievements in several indications, with an important part as sales milestones, as well as u... |
| Feb 25, 2022 | Tillman Gerngross leads a pack of biotech CEOs out the door; With eyes on pipeline expansion, Poseida woos a gene therapy exec from Novartis | Tillman Gerngross
As market volatility sweeps through the landscape, CEO changes are really ramping up, and topping the list is Tillman Gerngross, a force in the antibody space who hitched his wagon to finding another Covid-19 solution by c... |
| Jan 31, 2022 | Almirall S A : announces multi-target licensing agreement with Ablexis and collaboration with AlivaMab Discovery Services to accelerate antibody drug discovery and development | Almirall announces multi-target licensing agreement with Ablexis and collaboration with AlivaMab Discovery Services to accelerate antibody drug discovery and development 31 January 2022
Through this license agreement with Ablexis, Almirall ... |
| Dec 17, 2021 | Almirall S A : “Hoy sí me puedo levantar”, a campaign in support of people living with Multiple Sclerosis (MS) | "Hoy sí me puedo levantar", a campaign in support of people living with Multiple Sclerosis (MS) 17 December 2021
Almirall launches an awareness campaign with the support of EME, the patients' association Esclerosis Múltiple E... |
| Oct 28, 2021 | Almirall launches "Shedding Light on Psoriasis" campaign to raise awareness on World Psoriasis Day | Almirall launches "Shedding Light on Psoriasis" campaign to raise awareness on World Psoriasis Day 28 October 2021
The campaign aims to raise awareness on how psoriasis deeply impacts the wellbeing of people living with this long-... |
| Sep 27, 2021 | Almirall S A : launches Klisyri®▼(tirbanibulin) for the treatment of actinic keratosis in Europe | Almirall launches Klisyri®▼(tirbanibulin) for the treatment of actinic keratosis in Europe 27 September 2021
The UK and Germany are the first two European countries where Klisyri® will be available for prescription. The product has been app... |
| Jul 26, 2021 | Almirall delivers robust H1 performance and increases full-year guidance | |
| Jul 26, 2021 | Almirall S A : delivers robust H1 performance and increases full-year guidance | Almirall delivers robust H1 performance and increases full-year guidance 26 July 2021
Robust business performance with significant growth in Core EBITDA: Core Net Sales €415.5 MM (+8% year-on-year) and Core EBITDA reached €125.6 MM, (+40.4%... |
| Jul 19, 2021 | Almirall S A : receives European Commission approval of Klisyri®▼ (tirbanibulin), an innovative topical treatment for actinic keratosis | Almirall receives European Commission approval of Klisyri®▼(tirbanibulin), an innovative topical treatment for actinic keratosis 19 July 2021
Klisyri® (tirbanibulin) is a topical microtubule inhibitor indicated for the treatment of actinic ... |
| Jul 5, 2021 | Almirall S A : launches new call to establish partnerships in innovative therapies for skin diseases | Almirall launches new call to establish partnerships in innovative therapies for skin diseases 05 July 2021
AlmirallShare's new call aims to find opportunities on new assets in research or preclinical development stages that can be use... |
| Jul 1, 2021 | Almirall S A : and Kaken Pharmaceutical enter into a license and distribution agreement for European rights to the topical formulation of efinaconazole | Almirall and Kaken Pharmaceutical enter into a license and distribution agreement for European rights to the topical formulation of efinaconazole 01 July 2021
Efinaconazole is a triazole antifungal compound indicated for the treatment of fu... |
| Jun 17, 2021 | ALMIRALL, S.A.
Almirall S A : joins BIOMAP as a new partner to advance the field of inflammatory skin conditions | Almirall joins BIOMAP as a new partner to advance the field of inflammatory skin conditions 17 June 2021
BIOMAP is a European research project from the Innovative Medicines Initiative (IMI) focused on the two most common inflammatory skin c... |
| Jun 1, 2021 | ALMIRALL, S.A.
Almirall S A : receives FDA approval to produce Seysara ® (sarecycline) at the Sant Andreu de la Barca (Barcelona) plant | Almirall receives FDA approval to produce Seysara ® (sarecycline) at the Sant Andreu de la Barca (Barcelona) plant 01 June 2021
The production of this drug in Sant Andreu de la Barca (Barcelona) provides the company with a dual supply sourc... |
| May 21, 2021 | ALMIRALL, S.A.
Almirall S A : receives positive CHMP opinion for Klisyri®▼ (tirbanibulin), an innovative topical treatment for actinic keratosis | Almirall receives positive CHMP opinion for Klisyri®▼ (tirbanibulin), an innovative topical treatment for actinic keratosis 21 May 2021
Klisyri® (tirbanibulin) is a novel microtubule inhibitor, indicated for the topical treatment of actinic... |
| May 21, 2021 | Almirall receives positive CHMP opinion for Klisyri®▼ (tirbanibulin), an innovative topical treatment for actinic keratosis | |
| May 10, 2021 | Almirall's solid core business Q1 performance boosted by Growth drivers momentum | |
| May 6, 2021 | ALMIRALL, S.A.
Almirall S A : receives the qualification "Excellent" in the Profarma 2020 program | Almirall receives the qualification 'Excellent' in the Profarma 2020 program 05 May 2021
Almirall has obtained consecutively the highest qualification granted by this program since it was created in 1986
BARCELONA, Spain. May 5 20... |
| Feb 22, 2021 | Almirall's 2020 Full-Year Results | |
| Feb 18, 2021 | Almirall U.S. Launches Klisyri® (tirbanibulin), a New, Innovative Topical Treatment for Actinic Keratosis | |
| Feb 11, 2021 | Almirall announces New England Journal of Medicine publication of Phase III data demonstrating efficacy and safety of Klisyri® (tirbanibulin) | |
| Dec 15, 2020 | Almirall announces FDA approval of Klisyri® (tirbanibulin), a new innovative topical treatment for actinic keratosis | |
| Nov 24, 2020 | Almirall announces collaborations with the University of South Australia and Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
USA - English
USA - English
USA - English
Deutschland - Deutsch
Italia - Italiano | |
| Nov 9, 2020 | Almirall demonstrates resilient performance year to date despite COVID-19 impacts
USA - English
USA - English
Deutschland - Deutsch | |
| Oct 16, 2020 | Almirall launches its second innovation initiative for dermatology-focused digital health start-ups
USA - English
Deutschland - Deutsch | |
| Jul 22, 2020 | ALMIRALL, S.A.
Almirall S A : joins the AMR Action Fund to support the fight against antimicrobial resistance | Almirall joins the AMR Action Fund to support the fight against antimicrobial resistance 21 July 2020
Antimicrobial resistance (AMR) is considered one of the most urgent global medical challenges
More than 20 leading biopharmaceutical compa... |
| Jul 10, 2020 | ALMIRALL, S.A.
Almirall S A : joins the AMR Action Fund to support the fight against antimicrobial resistance | Almirall joins the AMR Action Fund to support the fight against antimicrobial resistance 10 July 2020
Antimicrobial resistance (AMR) is considered one of the most urgent global medical challenges
More than 20 leading biopharmaceutical compa... |
| Jan 9, 2020 | Congratulations 23andMe users, your genes are finally helping the company make drugs | All of that genetic material that 23andMe has been collecting is finally being used for commercial drug development — specifically dermatological drugs.
The company inked an agreement with Spanish pharmaceutical developer Almirall, which co... |
| Jul 29, 2015 | Daily funding roundup - July 29, 2015 | Twilio closed $130M; Mereo BioPharma secured $119; AltspaceVR raised $10.3M
AltspaceVR, a software company that uses virtual reality to provide a new communication platform, raised a $10.3 million round of funding. Investors in the round in... |
| Jul 30, 2014 | AstraZeneca agrees strategic transaction with Almirall in respiratory disease | AstraZeneca agrees strategic transaction with Almirall in respiratory disease
30-07-2014
Business combination will provide boost to revenue as well as creating long-term value, strengthening AstraZeneca’s respiratory franchise with a comple... |
